Immunovant Gets Positive Data From Graves' Disease Treatment Trial
By Sabela Ojea
Immunovant said it received positive data from its ongoing 24-week Phase 2 clinical trial for its batoclimab treatment for Graves' disease.
The clinical-stage immunology company on Wednesday said the trial results in patients with Graves' disease meaningfully exceeded 50% response rates.
Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.
Graves' disease is an immune system disorder.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
December 20, 2023 17:25 ET (22:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
4 New Stocks to Buy With Catalysts for Future Gains
-
Markets Brief: Q2 Earnings Season Begins With the Banks
-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
The 10 Best Dividend Stocks
-
3 Smaller-Company Stocks the Best Fund Managers Are Buying
-
SolarEdge Stock Is Down 74% In 2024. Is It a Buy or a Sell?
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities